Fibrocell files IND for gene therapy to treat scleroderma; shares up 2% – Seeking Alpha
|
Fibrocell files IND for gene therapy to treat scleroderma; shares up 2%
Seeking Alpha Fibrocell Science (FCSC +2%) has submitted an Investigational New Drug (IND) application to the FDA seeking approval to launch a clinical trial evaluating gene therapy candidate FCX-013 in patients with moderate-to-severe localized scleroderma, an … Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to … Fibrocell Science (NASDAQ:FCSC) Rating Increased to Buy at Zacks Investment Research |
